Patents by Inventor Xinli Pang

Xinli Pang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS
    Publication number: 20210206829
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 8, 2021
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
  • Treatment of CD47+ disease cells with SIRP?-Fc fusions
    Patent number: 10906954
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: February 2, 2021
    Assignee: TRILLIUM THERAPEUTICS INC.
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
  • Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions
    Publication number: 20180312563
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Application
    Filed: April 25, 2018
    Publication date: November 1, 2018
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
  • Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
    Patent number: 9969789
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 15, 2018
    Assignee: TRILLIUM THERAPEUTICS INC.
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang
  • Treatment of CD47+ Disease Cells with SIRP Alpha-FC Fusions
    Publication number: 20150329616
    Abstract: CD47+ disease cells, such as CD47+ cancer cells, are treated with an agent that blocks signalling via the SIRP?/CD47 axis. The agent is a human SIRP? fusion protein that displays negligible CD47 agonism and negligible red blood cell binding. The fusion protein comprises an IgV domain from variant 2 of human SIRP?, and an Fc having effector function. The IgV domain binds human CD47 with an affinity that is at least five fold greater than the affinity of the entire extracellular region of human SIRP?. The fusion protein is at least 5 fold more potent than a counterpart lacking effector function.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 19, 2015
    Applicant: TRILLIUM THERAPEUTICS INC.
    Inventors: Robert Adam Uger, Penka Slavtcheva Slavova-Petrova, Xinli Pang